Discovery and Developmental Therapeutics

项目总结/摘要 发现和发展治疗学（DDT）计划提供了一个平台， 将新发现纳入Winship翻译管道，并用于开发新的癌症诊断和 治疗方法，前提是滴滴涕之间的跨学科和跨学科相互作用 成员提出有效的抗癌策略。该计划围绕四个科学主题组织：（1） 发现，治疗靶点和新型小分子的发现和彻底评估;（2）癌症 成像，体内成像剂的开发和/或利用，以及用于药物递送和用于 非侵入性诊断和治疗癌症的应用;（3）癌症免疫治疗，翻译 创新的免疫概念和抗癌治疗方法;和（4）发展治疗学， 使用新的治疗策略和个体化治疗选择的癌症人类干预试验 通过充当靶点、成像、治疗剂和药物的翻译的汇聚点， 免疫疗法这四个科学主题引领着该计划的活动，以及计划内和计划间的活动。 通过Winship提供的资源和基础设施进行研究。 在Haian Fu博士（领导人）和Suresh Ramalingam博士（共同领导人）的领导下，滴滴涕 该计划包括56名核心成员，代表医学院内的16个不同部门 (SOM)罗林斯公共卫生学院（RSPH）和埃默里学院。2012年至今， 高度协作的研究人员小组发表了1，122篇与癌症相关的科学文章。其中，296 (26 273项（24%）是计划内合作，445项（40%）涉及 与其他癌症中心或学术组织合作。截至2016年3月31日，DDT成员 每年持有埃默里大学授予的癌症相关研究资金总额为2840万美元， 其中约980万美元（34%）直接来自NCI。此外，滴滴涕成员国 Curran通过NRG肿瘤学基金会以多PI格式获得了1500万美元的NCI支持。建造 关于Winship为有效药物和靶点发现提供的资源和基础设施， 随后的翻译发展，并根据成员之间建立的互动，滴滴涕 该计划正在为开发有效的诊断和治疗方案做出重大贡献 for cancer癌症patients病人.

PROJECT SUMMARY/ABSTRACT The Discovery and Developmental Therapeutics (DDT) Program provides a platform for integration of discoveries into the Winship translational pipeline and for development of new cancer diagnostic and therapeutic approaches with the premise that interdisciplinary and transdisciplinary interactions among DDT members advance effective anti-cancer strategies. The program is organized around four scientific themes: (1) Discovery, the discovery and thorough evaluation of therapeutic targets and novel small molecules; (2) Cancer Imaging, the development and/or utilization of in vivo imaging agents and technologies for drug delivery and for non-invasive diagnostic and therapeutic cancer applications; (3) Cancer Immunotherapy, the translation of innovative immune concepts and approaches into anti-cancer therapies; and (4) Developmental Therapeutics, human interventional trials for cancer using novel therapeutic strategies and individualized treatment options by functioning as a convergence point for translation of targets, imaging, therapeutic agents, and immunotherapies. These four scientific themes lead the program's activities and intra- and inter-programmatic research efforts through resources and infrastructure provided by Winship. Under the leadership of Haian Fu, PhD (leader) and Suresh Ramalingam, MD (co-leader) the DDT Program includes 56 core members representing 16 different departments within the School of Medicine (SOM), Rollins School of Public Health (RSPH), and Emory College. Between 2012 and the present this highly collaborative group of researchers published 1,122 cancer-relevant scientific articles. Of these, 296 (26%) were intra- and 273 (24%) were inter-programmatic collaborations, and 445 (40%) involved a collaboration with another cancer center or academic organization. As of March 31, 2016, DDT members held $28.4 million in annual total cancer-relevant research funding as awarded through Emory University, of which approximately $9.8 million (34%) was awarded directly from the NCI. In addition, DDT member Curran received $15M of NCI support as PI in a multi-PI format through the NRG Oncology Foundation. Built on Winship's enabling resources and infrastructure for effective drug and target discovery and their subsequent translational development and based on established interactions among members, the DDT Program is making major contributions to the development of efficacious diagnostic and treatment options for cancer patients.